Cargando…

Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor

This case is a reminder not to overlook rare causes of electrolyte shifts, which may cause reversible changes in pacemaker pacing thresholds.

Detalles Bibliográficos
Autores principales:	Asbach, Stefan, Schluermann, Fabienne, Ruf, Juri, Bode, Christoph, Lang, Corinna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5771922/ https://www.ncbi.nlm.nih.gov/pubmed/29375864 http://dx.doi.org/10.1002/ccr3.1271

Ejemplares similares

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
por: Starr, Jason S, et al.
Publicado: (2020)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours
por: Lim, Lisi Elizabeth, et al.
Publicado: (2020)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021)

Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

SUN-914 Peptide Receptor Radionuclide Therapy for an Inoperable Small Cell Neuroendocrine Tumor in the Philippines
por: Alegria, Rainier Mark Gabriel
Publicado: (2020)

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
por: Liberini, Virginia, et al.
Publicado: (2020)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
por: Camus, Baptiste, et al.
Publicado: (2021)

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
por: Opalińska, Marta, et al.
Publicado: (2021)

Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy
por: Hendifar, Andrew E., et al.
Publicado: (2022)

Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors
por: Hasegawa, Sho, et al.
Publicado: (2022)

Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
por: Severi, Stefano, et al.
Publicado: (2017)

Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors
por: Kipnis, Sarit T., et al.
Publicado: (2021)

Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases
por: Ngongoni, Rejoice, et al.
Publicado: (2022)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

(225)Ac-MACROPATATE: A Novel α-Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors
por: King, A. Paden, et al.
Publicado: (2023)

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo
por: Reuvers, Thom G.A., et al.
Publicado: (2023)

Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy
por: Ohlendorf, Fiona, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Potentiation of (177)Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor
por: Purohit, Nupur K., et al.
Publicado: (2018)

External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy
por: Das, Satya, et al.
Publicado: (2022)

Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
por: Pusceddu, Sara, et al.
Publicado: (2022)

Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report
por: Kumar, Amit, et al.
Publicado: (2022)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review
por: Huizing, Daphne Merel Valerie, et al.
Publicado: (2018)

Radiation precautions for inpatient and outpatient (177)Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours
por: Levart, D., et al.
Publicado: (2019)

Neuroendocrine metastasis to the thyroid from unknown primary and extrathyroidal disease response to peptide receptor radionuclide therapy
por: Khessib, Tasnim, et al.
Publicado: (2023)

A Care Process Model to Deliver (177)Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2019)

(177)Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Metastatic or Advanced and Inoperable Primary Neuroendocrine Tumors of Rare Sites
por: Thapa, Pradeep, et al.
Publicado: (2017)

Therapy‐related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor
por: Kucukyurt, Selin, et al.
Publicado: (2020)

Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
por: Grey, Neil, et al.
Publicado: (2022)

Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
por: Zhu, Mojun, et al.
Publicado: (2022)

Safety and efficacy of peptide receptor radionuclide therapy with (177)Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
por: Jiang, Yuanyuan, et al.
Publicado: (2022)

Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE
por: Prétot, Dominique, et al.
Publicado: (2023)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
por: Yordanova, Anna, et al.
Publicado: (2020)

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)
por: Sowa-Staszczak, Anna, et al.
Publicado: (2011)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy
por: Braat, A. J. A. T., et al.
Publicado: (2019)

PLGA Nanoparticles for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Novel Approach towards Reduction of Renal Radiation Dose
por: Arora, Geetanjali, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9ckp5ps59sl370jrh69aelr2je